Close Menu

NEW YORK (GenomeWeb) – Paradigm Diagnostics today announced the first closing of what it expects to be a $7 million Series B financing to support the rapid commercial expansion of its PCDx tumor sequencing test.

The first tranche of the funding round, which raised $3.5 million, was led by Mesa Verde Venture Partners. Mesa Verde managing director Carey Ng also joined Paradigm's board.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.